Table 4.

Comparison of intent-to-treat postremission treatment groups

IDAC-1
IDAC-2
HDAC-2
CHEMO*
ALLO
Patients, no.   22   17   47   72   16  
Study, no.       
    LAME-91   0   17   0   17   6  
    ALFA-9000   22   0   0   17   0  
    BGMT-87   0   0   6   6   5  
    BGMT-91   0   0   10   8   1  
    GOELAM-01   0   0   9   7   0  
    GOELAM-02   0   0   22   17   4  
Sex, M/F   10/12   8/9   27/20   36/36   9/7  
Median age, y (range)   35 (15-64)   5 (0.7-16)   43 (18-59)   32 (0.7-49)   24 (1.9-39)  
Median WBC, × 109/L (range)   35 (3-228)   84 (7-240)   28 (3-186)   43 (3-240)   41 (8-238)  
Associated chromosome abnormalities, no.   8   3   15   20   4  
AN/AA status, † no.   9/12   10/7   19/28   32/39   6/10  
Two cycles required for CR achievement, no.
 		 2
 		 0
 		 3
 		 3
 		 0
 
IDAC-1
IDAC-2
HDAC-2
CHEMO*
ALLO
Patients, no.   22   17   47   72   16  
Study, no.       
    LAME-91   0   17   0   17   6  
    ALFA-9000   22   0   0   17   0  
    BGMT-87   0   0   6   6   5  
    BGMT-91   0   0   10   8   1  
    GOELAM-01   0   0   9   7   0  
    GOELAM-02   0   0   22   17   4  
Sex, M/F   10/12   8/9   27/20   36/36   9/7  
Median age, y (range)   35 (15-64)   5 (0.7-16)   43 (18-59)   32 (0.7-49)   24 (1.9-39)  
Median WBC, × 109/L (range)   35 (3-228)   84 (7-240)   28 (3-186)   43 (3-240)   41 (8-238)  
Associated chromosome abnormalities, no.   8   3   15   20   4  
AN/AA status, † no.   9/12   10/7   19/28   32/39   6/10  
Two cycles required for CR achievement, no.
 		 2
 		 0
 		 3
 		 3
 		 0
 

WBC indicates white blood cell count.

*

This CHEMO group comprised all patients from the IDAC-1, IDAC-2, and HDAC-2 groups if aged 50 years or younger.

†

In 101 CR patients with at least 5 analyzed metaphases.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal